Phaseline

Companies › Pulmovant

Pulmovant: clinical trials, targets and expected readouts

1 active drug program in 3 registered trials: 2 Phase 2, 1 Phase 3; Cardiovascular; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
inhaled mosliciguat
soluble guanylate cyclase stimulator
GUCY1A1, GUCY1B1Phase 3Pulmonary HypertensionDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07333183inhaled mosliciguatPhase 2Pulmonary HypertensionCardiovascularDec 2026
NCT06635850inhaled mosliciguatPhase 2Pulmonary HypertensionCardiovascularJan 2028
NCT07816185inhaled mosliciguatPhase 3Pulmonary HypertensionCardiovascularJan 2029

Targets

GUCY1A1 (1) GUCY1B1 (1)

Companies with the same targets

Merck & Co. (MSD) Kardigan Coherus Oncology Bayer Akebia Therapeutics

Companies built like this

Trust Bio-sonics Liquidia Technologies EVD Pharmacy and Medical Company EBI Anti Sepsis Agitated Solutions

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.